Helius Medical Technologies calls the out-of-network reimbursement the first step in making the PoNS device more accessible to MS patients.

Depending on the individual’s deductible and out-of-pocket costs, this claim may not result in an immediate PoNS Device sale. About the PoNS Device and PoNS Therapy The Portable Neuromodulation ...

Helius Medical Technologies (NASDAQ:HSDT) shares are trading higher Wednesday after the company announced an authorized claim ...

CMSC attendees were encouraged at Helius' recent successes in obtaining initial reimbursement from federal and private payers ...

Helius Medical Technologies will present significant new study results at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting, showcasing the sustained efficacy of its PoNS® device.

The PoNS device is a non-implantable, orally applied therapy that delivers neurostimulation through a mouthpiece to improve balance and gait. It is FDA-authorized as a short-term treatment for ...

A new wave of innovation is reshaping small-cap markets across sectors including oncology, functional energy beverages, ...

At the November 8 th HCPCS Level 2 Public meeting we again refuted CMS’ methodology and presented compelling evidence in support of fair pricing for the PoNS device. Our diligent response and ...

Helius Medical Technologies, Inc. (Nasdaq: HSDT) announced that Aetna Healthcare has authorized a claim for reimbursement for ...

Aetna authorizes claim for PoNS Device at out-of-network negotiated price of $18,350, becoming the third payer to join Anthem and United in providing PoNS reimbursement- -Out of Network ...